KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Liabilities (2016 - 2025)

Historic Total Liabilities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $329.3 million.

  • CRISPR Therapeutics AG's Total Liabilities rose 406.17% to $329.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.3 million, marking a year-over-year increase of 406.17%. This contributed to the annual value of $310.0 million for FY2024, which is 1061.63% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Total Liabilities of $329.3 million as of Q3 2025, which was up 406.17% from $318.6 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's Total Liabilities' 5-year high stood at $399.4 million during Q3 2022, with a 5-year trough of $152.4 million in Q1 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Total Liabilities had a median value of $352.4 million in 2021 and averaged $337.5 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 13702.79% in 2022, then tumbled by 1185.51% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Total Liabilities stood at $352.4 million in 2021, then rose by 4.3% to $367.6 million in 2022, then decreased by 5.66% to $346.8 million in 2023, then decreased by 10.62% to $310.0 million in 2024, then grew by 6.25% to $329.3 million in 2025.
  • Its last three reported values are $329.3 million in Q3 2025, $318.6 million for Q2 2025, and $336.9 million during Q1 2025.